GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eyenovia Inc (NAS:EYEN) » Definitions » 3-Year FCF Growth Rate

Eyenovia (Eyenovia) 3-Year FCF Growth Rate : -29.00% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eyenovia 3-Year FCF Growth Rate?

Eyenovia's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.22.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -29.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 9 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Eyenovia was 16.60% per year. The lowest was -59.60% per year. And the median was -8.10% per year.


Competitive Comparison of Eyenovia's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Eyenovia's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eyenovia's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eyenovia's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Eyenovia's 3-Year FCF Growth Rate falls into.



Eyenovia 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Eyenovia  (NAS:EYEN) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Eyenovia 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Eyenovia's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Eyenovia (Eyenovia) Business Description

Traded in Other Exchanges
N/A
Address
295 Madison Avenue, Suite 2400, New York, NY, USA, 10017
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
Executives
Michael M Rowe director, officer: Chief Executive Officer C/O EYENOVIA, INC., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Ellen R Strahlman director ALTRIA GROUP, INC., 6601 W. BROAD STREET, RICHMOND VA 23230
Stuart M. Grant 10 percent owner 11 SUMMIT LANE, GREENVILLE DE 19807
Ram Palanki director C/O EYENOVIA, INC, 295 MADISON AVENUE SUITE 2400, NEW YORK NY 10017
Rachel Jacobson director C/O EYENOVIA INC, 295 MADISON AVENUE SUITE 2400, NEW YORK NY 10017
John P Gandolfo officer: Chief Financial Officer 62 TERRACE ROAD, WAYNE NJ 07470
Bren Kern officer: Chief Operating Officer 295 MADISON AVENUE, SUITE 2400, C/O EYENOVIA, INC., NEW YORK NY 10017
Mather Charles E Iv director C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Tsontcho Ianchulev director 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Stephen Keith Benjamin director 135 NORTH CHURCH STREET, SPARTANBURG SC 29306
Julia A Haller director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Lee Kenneth B Jr director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Curt H Labelle director C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Anthony Y Sun director C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106
Fredric N Eshelman director PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401